Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.3% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment reporting

Analytics

Phase 2/3
2(50.0%)
N/A
2(50.0%)
4Total
Phase 2/3(2)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT04299893Phase 2/3Recruiting

Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)

Role: collaborator

NCT05417737Active Not Recruiting

Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025

Role: collaborator

NCT03282695Completed

Ozone Therapy in Patients on Waiting List for Surgery Due to Disc Herniation: Prospective, Post-authorization Study

Role: collaborator

NCT04147130Not ApplicableCompleted

MultiPAP Plus: Improving Prescription in Primary Care Patients With Multimorbidity and Polypharmacy

Role: collaborator

NCT03660657Phase 2/3Terminated

Ozone Therapy in Refractory Ischemic Heart Disease.

Role: collaborator

NCT02866799Not ApplicableCompleted

Multi-PAP: Improving Prescription in Primary Care Patients With Multimorbidity and Polypharmacy

Role: collaborator

NCT03846999Completed

Comorbidities and Health Care Services Utilisation Among Long-term Breast Cancer Survivors

Role: collaborator

NCT03165006Completed

Effect of Interval Cancer and Screening Process on Survival and Disease-free Period in Breast Cancer

Role: collaborator

All 8 trials loaded